Comments
Aurobindo Pharma Ltd has received the final approval from the US Food and& Drug Administration (USFDA) to manufacture and market ‘potassium chloride extended-release’ tablets.
The tablets are a generic version of Upsher-Smith’s Klor-Con extended release tablets. The product will be launched in January 2019. Potassium chloride tablets are indicated for the treatment of hypokalemia, with or without metabolic alkalosis, in digitalis intoxication, and in hypokalemic familial periodic paralysis.
The approved product had an estimated market size of about $ 60 million in the 12- month period ended October 2018, according to IQVIA.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.